by Patients may have resigned weight loss medication such as Ozempic and unplugation by overgrowing within weeks after stopping, as a new study stated.
The Research Review, published on Tuesday in the magazine BMC medicineRated data from 11 earlier clinical studies in which almost 2,500 people were involved and found a broad trend of patients who take off again after completing their medication courses.
So far, at least six medication for the treatment of obesity in adult orlistat, Naltrexon-Bupropion, Semaglutid, Liraglutide, Tirzepatid and Phententin-Topiramate.
Six of the 11 clinical studies treated in the review focused on Semaglutid, the active ingredient of Ozempic and Wegovy.
While a growing group of investigations shows that a longer use of these anti-ad fosterity medicines in adults can lead to a significant weight loss, preliminary studies indicate that the weight regulations regain.
“The long -term change in weight after stopping AOMs still lacks a systematic evaluation,” states the new review, with reference to medication against adjicity.
The Semaglutid is first handed over to patients with obesity and type 2 diabetes and is now sold as a quick fix for weight loss.
Researchers, including the Peking University in China, have now found that Semaglutid and similar drugs could lead to a significant weight loss, but could begin a weight recreation can hardly begin eight weeks after it was sent.
Representation. A pharmacy owner talks to a customer in a pharmacy in Pristina (AFP via Getty)
In the review, the researchers analyzed data from 1,574 participants in treatment groups and 893 in control groups in 11 clinical studies, which measured the change of weight by persecution of body weight and the BMI after completing the medication.
Researchers controlled the contribution of factors, including the type of medication, presence of diabetes and presence or lack of changes in lifestyle such as nutrition or movement. The analysis showed that the weight yield lasted an average of 20 weeks after demolition before the platea.
“Significant weight was performed eight weeks after stopping the AOMs and was maintained in 20 weeks,” they write in the review.
The participants experienced significant weight periods at eight, 12 and 20 weeks after the end of the medication, as the study found.
The weight yield seemed to hang out of factors such as the type of medication taken and the consistency of lifestyle.
For example, patients who have completed a 36-week treatment of Tirepatide with weight loss medication have almost half of the previously lost weight after switching to placebo.
The review requires more studies with longer follow-up periods to further evaluate potential factors that are associated with the change in weight after the treatment of treatment is adjusted with such drugs.
